Genomic profiling of mantle cell lymphoma

Methods in Molecular Biology

Volumn 973, Issue , 2013, Pages 147-163

  Menanteau, Melissa Rieger ^a   Martinez Climent, Jose A ^a  

^a NONE

Author keywords

Comparative genomic hybridization; Cyclin D1; Genomic abnormalities; Mantle cell lymphoma; Predictive factors of therapeutic response; Prognostic factors

Indexed keywords

ARF PROTEIN; BMI1 PROTEIN; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2C; MICRORNA 16; PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR SOX11;

ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA DAMAGE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; MANTLE CELL LYMPHOMA; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR GENE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UNIPARENTAL DISOMY; GENETICS; METHODOLOGY; PATHOLOGY; PROGNOSIS;

CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN D1; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, MANTLE-CELL; PROGNOSIS; UNIPARENTAL DISOMY;

MLCS; MLOWN;

EID: 84880765334     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-281-0_9     Document Type: Article

References (113)

1. Swerlow SH, Berger F, Isaacson P., Muller-Hermelink HK, Nathwani BN, Piris M.A., Harris N.L. (2001) Mantle cell lymphoma. World Health Organization Classification of tumors pathology and genetics of tumours of haematopoietic and lymphoid tissues: 168-170
2. Orchard J, Garand R, Davis Z et al (2003) A subset of t(11;14) lymphoma with mantle cell features displays mutated igvh genes and includes patients with good prognosis, non-nodal disease. Blood 101(12): 4975-4981. doi: 10.1182/blood-2002-06-18642002-06-1864 [pii]
3. Rubio-Moscardo F., Climent J, Siebert R et al (2005) Mantle-cell lymphoma genotypes identified with cgh to bac microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105(11): 4445-4454. doi: 2004-10-3907 [pii] 10.1182/blood-2004-10-3907
4. Fernandez V, Salamero O, Espinet B et al (2010) Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70(4): 1408-1418. doi: 0008-5472.CAN-09-3419 [pii] 10.1158/0008-5472.CAN-09-3419
5. Dreyling M, Hiddemann W. (2008) Doseintense treatment of mantle cell lymphoma: can durable remission be achieved? Curr Opin Oncol 20(5): 487-494. doi: 10.1097/CCO.0b013e32830b61c200001622-200809000-00002 [pii]
6. Witzig TE (2005) Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 23(26): 6409-6414. doi: 23/26/6409 [pii] 10.1200/JCO.2005.55.017
7. O'connor OA (2007) Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways. Hematology Am Soc Hematol Educ Program: 270-276. doi: 2007/1/270 [pii] 10.1182/asheducation-2007.1.270
8. Leonard JP, Williams ME, Goy A et al (2009) Mantle cell lymphoma: biological insights and treatment advances. Clin L ymphoma Myeloma 9(4): 267-277. doi: 11G5T6V781XQ3127 [pii] 10.3816/CLM.2009.n.055
9. Campo E, Raffeld M, Jaffe E.S. (1999) Mantle-cell lymphoma. Semin Hematol 36(2): 115-127
10. Rosenberg CL, Wong E, Petty EM et al (1991) Prad1, a candidate bcl1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88(21): 9638-9642
11. Bosch F, Jares P, Campo E et al (1994) Prad-1/cyclin d1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lym-phoma. Blood 84(8): 2726-2732
12. Wlodarska I, Meeus P, Stul M et al (2004) Variant t(2;11)(p11;q13) associated with the igk-ccnd1 rearrangement is a recurrent trans-location in leukemic small-cell b-non-hodgkin lymphoma. Leukemia 18(10): 1705-1710. doi: 10.1038/sj.leu.24034592403459 [pii]
13. Komatsu H, Iida S, Yamamoto K et al (1994) A variant chromosome translocation at 11q13 identifying prad1/cyclin d1 as the bcl-1 gene. Blood 84(4): 1226-1231
14. Rocha CK, Praulich I, Gehrke I et al (2011) A rare case of t(11;22) in a mantle cell lymphoma like b-cell neoplasia resulting in a fusion of igl and ccnd1: case report. Mol Cytogenet 4(1): 8. doi: 1755-8166-4-8 [pii] 10.1186/1755-8166-4-8
15. Espinet B, Salaverria I, Bea S et al (2010) Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 49(5): 439-451. doi: 10.1002/gcc.20754
16. Gruszka-Westwood A.M., Atkinson S, Summersgill BM et al (2002) Unusual case of leukemic mantle cell lymphoma with amplified ccnd1/igh fusion gene. Genes Chromosomes Cancer 33(2): 206-212. doi: 10.1002/gcc.1216 [pii]
17. Ott G, Kalla J, Ott MM et al (1997) Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 89(4): 1421-1429
18. Kramer A, Schweizer S, Neben K et al (2003) Centrosome aberrations as a possible mechanism for chromosomal instability in non-hodgkin's lymphoma. Leukemia 17(11): 2207-2213. doi: 10.1038/sj.leu.24031422403142 [pii]
19. Neben K, Ott G, Schweizer S et al (2007) Expression of centrosome-associated gene products is linked to tetraploidization in mantle cell lymphoma. Int J Cancer 120(8): 1669-1677. doi: 10.1002/ijc.22404
20. Tirier C, Zhang Y, Plendl H et al (1996) Simultaneous presence of t(11;14) and a variant burkitt's translocation in the terminal phase of a mantle cell lymphoma. Leukemia 10(2): 346-350
21. Vaishampayan UN, Mohamed AN, Dugan MC et al (2001) Blastic mantle cell lymphoma associated with burkitt-type translocation and hypodiploidy. Br J Haematol 115(1): 66-68. doi: 3056 [pii]
22. Hao S, Sanger W, Onciu M et al (2002) Mantle cell lymphoma with 8q24 chromosomal abnor-malities: a report of 5 cases with blastoid features. Mod Pathol 15(12): 1266-1272. doi: 10.1097/01.Mp.0000037310.82136.99
23. Michaux L, Wlodarska I, Theate I et al (2004) Coexistence of bcl1/ccnd1 and cmyc aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome. Ann Hematol 83(9): 578-583. doi: 10.1007/s00277-004- 0879-2
24. Oliveira FM, Tone LG, Simoes BP et al (2007) Blastoid mantle cell lymphoma with t(2;8) (p12;q24). Leuk Lymphoma 48(10): 2079-2082. doi: 782725470 [pii] 10.1080/10428190701606834
25. Rosenwald A, Wright G, Wiestner A et al (2003) The proliferation gene expression signature is a quantitative integrator of onco-genic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2): 185-197. doi: S153561080300028X [pii]
26. Hinds PW, Dowdy SF, Eaton EN et al (1994) Function of a human cyclin gene as an onco-gene. Proc Natl Acad Sci USA 91(2): 709-713
27. Lovec H, Grzeschiczek A, Kowalski MB et al (1994) Cyclin d1/bcl-1 cooperates with myc genes in the generation of b-cell lymphoma in transgenic mice. EMBO J 13(15): 3487-3495
28. Bodrug SE, Warner BJ, Bath ML et al (1994) Cyclin d1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 13(9): 2124-2130
29. Gladden AB, Woolery R, Aggarwal P et al (2006) Expression of constitutively nuclear cyclin d1 in murine lymphocytes induces b-cell lymphoma. Oncogene 25(7): 998-1007. doi: 1209147 [pii] 10.1038/sj.onc.1209147
30. Beltran E, Fresquet V, Martinez-Useros J et al (2011) A cyclin-d1 interaction with bax underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. Proc Natl Acad Sci USA 108(30): 12461-12466. doi: 1018941108 [pii] 10.1073/pnas.1018941108
31. Wong KK, Tsang YT, Shen J et al (2004) Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (snp) array with whole genome amplified DNA. Nucleic Acids Res 32(9): e69. doi: 10.1093/nar/gnh07232/9/e69 [pii]
32. Cutler DJ, Zwick ME, Carrasquillo MM et al (2001) High-throughput variation detection and genotyping using microarrays. Genome Res 11(11): 1913-1925. doi: 10.1101/gr.197201
33. Ishkanian AS, Malloff CA, Watson SK et al (2004) A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 36(3): 299-303. doi: 10.1038/ng1307ng1307 [pii]
34. Snijders AM, Nowak N, Segraves R et al (2001) Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 29(3): 263-264. doi: 10.1038/ng754ng754 [pii]
35. Pollack JR, Perou CM, Alizadeh AA et al (1999) Genome-wide analysis of DNA copy-number changes using cdna microarrays. Nat Genet 23(1): 41-46. doi: 10.1038/12640
36. Kallioniemi A, Kallioniemi OP, Sudar D et al (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258(5083): 818-821
37. Pinkel D, Segraves R, Sudar D et al (1998) High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20(2): 207-211. doi: 10.1038/2524
38. Pinkel D, Albertson D.G. (2005) Comparative genomic hybridization. Annu Rev Genomics Hum Genet 6: 331-354. doi: 10.1146/annurev.genom.6.080604.162140
39. Pinkel D, Albertson D.G. (2005) Array comparative genomic hybridization and its applications in cancer. Nat Genet 37(Suppl): S11-S17. doi: ng1569 [pii] 10.1038/ng1569
40. Royo C, Salaverria I, Hartmann EM et al (2011) The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 21(5): 322-334. doi: S1044-579X(11)00056-3 [pii] 10.1016/j.semcancer.2011.09.007
41. Fernandez V, Hartmann E, Ott G et al (2005) Pathogenesis of mantle-cell lymphoma: all onco-genic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23(26): 6364-6369. doi: 23/26/6364 [pii] 10.1200/JCO.2005.05.019
42. Jares P, Colomer D, Campo E. (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7(10): 750-762. doi: nrc2230 [pii] 10.1038/nrc2230
43. Perez-Galan P., Dreyling M, Wiestner A. (2010) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117(1): 26-38. doi: blood-2010-04-189977 [pii] 10.1182/blood-2010-04- 189977
44. Monni O, Oinonen R, Elonen E et al (1998) Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 21(4): 298-307. doi: 10.1002/(SICI)1098-2264(199804)21:4<298::AID-GCC3>3. 0.CO;2-U [pii]
45. Bea S, Ribas M, Hernandez JM et al (1999) Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93(12): 4365-4374
46. Cuneo A, Bigoni R, Rigolin GM et al (1999) Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobio-logic features. Blood 93(4): 1372-1380
47. Bentz M, Plesch A, Bullinger L et al (2000) T(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with b-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 27(3): 285-294. doi: 10.1002/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.0.CO;2-M [pii]
48. Bigoni R, Cuneo A, Milani R et al (2001) Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies. Leuk Lymphoma 40(5-6): 581-590. doi: 10.3109/10428190109097656
49. Martinez-Climent J.A., Vizcarra E, Sanchez D et al (2001) Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 98(12): 3479-3482
50. Allen JE, Hough RE, Goepel JR et al (2002) Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br J Haematol 116(2): 291-298. doi: 3260 [pii]
51. Bea S, Tort F, Pinyol M et al (2001) Bmi-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61(6): 2409-2412
52. Hernandez L, Bea S, Pinyol M et al (2005) Cdk4 and mdm2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type ink4a/arf locus. Cancer Res 65(6): 2199-2206. doi: 65/6/2199 [pii] 10.1158/0008-5472.CAN-04-1526
53. Pinyol M, Hernandez L, Cazorla M et al (1997) Deletions and loss of expression of p16ink4a and p21waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89(1): 272-280
54. Dreyling MH, Bullinger L, Ott G et al (1997) Alterations of the cyclin d1/p16-prb pathway in mantle cell lymphoma. Cancer Res 57(20): 4608-4614
55. Greiner TC, Dasgupta C, Ho VV et al (2006) Mutation and genomic deletion status of ataxia telangiectasia mutated (atm) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 103(7): 2352-2357. doi: 0510441103 [pii] 10.1073/pnas.0510441103
56. Salaverria I, Zettl A, Bea S et al (2007) Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 25(10): 1216-1222. doi: JCO.2006.08.4251 [pii] 10.1200/JCO.2006.08.4251
57. Stilgenbauer S, Winkler D, Ott G et al (1999) Molecular characterization of 11q deletions points to a pathogenic role of the atm gene in mantle cell lymphoma. Blood 94(9): 3262-3264
58. Hartmann EM, Campo E, Wright G et al (2010) Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 116(6): 953-961. doi: blood-2010-01-263806 [pii] 10.1182/blood-2010-01-263806
59. Camacho E, Hernandez L, Hernandez S et al (2002) Atm gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99(1): 238-244
60. Greiner TC, Moynihan MJ, Chan WC et al (1996) P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87(10): 4302-4310
61. Kohlhammer H, Schwaenen C, Wessendorf S et al (2004) Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 104(3): 795-801. doi: 10.1182/blood-2003-12-41752003-12-4175 [pii]
62. Schrader C, Janssen D, Klapper W et al (2005) Minichromosome maintenance protein 6, a proliferation marker superior to ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer 93(8): 939-945. doi: 6602795 [pii] 10.1038/sj.bjc.6602795
63. Tagawa H, Karnan S, Suzuki R et al (2005) Genome-wide array-based cgh for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene bim. Oncogene 24(8): 1348-1358. doi: 1208300 [pii] 10.1038/sj.onc.1208300
64. Flordal Thelander E., Ichimura K, Collins VP et al (2007) Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 31(9): 1219-1230. doi: S0145-2126(06)00415-2 [pii] 10.1016/j.leukres.2006.10.022
65. De Leeuw R.J., Davies JJ, Rosenwald A et al (2004) Comprehensive whole genome array cgh profiling of mantle cell lymphoma model genomes. Hum Mol Genet 13(17): 1827-1837. doi: 10.1093/hmg/ddh195ddh195 [pii]
66. Nielander I, Martin-Subero JI, Wagner F et al (2006) Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma. Leukemia 20(5): 904-905. doi: 2404173 [pii] 10.1038/sj.leu.2404173
67. Rinaldi A, Kwee I, Taborelli M et al (2006) Genomic and expression profiling identifies the b-cell associated tyrosine kinase syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 132(3): 303-316. doi: BJH5883 [pii] 10.1111/j.1365-2141.2005.05883.x
68. Vater I, Wagner F, Kreuz M et al (2009) Genechip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol 144(3): 317-331. doi: BJH7443 [pii] 10.1111/j.1365-2141.2008.07443.x
69. Bea S, Salaverria I, Armengol L et al (2009) Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution wholegenome profiling. Blood 113(13): 3059-3069. doi: blood-2008-07-170183 [pii] 10.1182/blood-2008-07-170183
70. Kawamata N, Ogawa S, Gueller S et al (2009) Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 37(8): 937-946. doi: S0301-472X(09)00175-1 [pii] 10.1016/j.exphem.2009.04.012
71. Halldorsdottir AM, Sander B, Goransson H et al (2011) High-resolution genomic screening in mantle cell lymphoma-specific changes correlate with genomic complexity, the proliferation signature and survival. Genes Chromosomes Cancer 50(2): 113-121. doi: 10.1002/gcc.20836
72. Mestre-Escorihuela C., Rubio-Moscardo F, Richter JA et al (2007) Homozygous deletions localize novel tumor suppressor genes in b-cell lymphomas. Blood 109(1): 271-280. doi: blood-2006-06-026500 [pii] 10.1182/blood-2006-06- 026500
73. Rubio-Moscardo F., Blesa D, Mestre C et al (2005) Characterization of 8p21.3 chromosomal deletions in b-cell lymphoma: trail-r1 and trail-r2 as candidate dosage-dependent tumor suppressor genes. Blood 106(9): 3214-3222. doi: 2005-05-2013 [pii] 10.1182/blood-2005-05-2013
74. Pinyol M, Bea S, Pla L et al (2007) Inactivation of rb1 in mantle-cell lymphoma detected by nonsense-mediated mrna decay pathway inhibition and microarray analysis. Blood 109(12): 5422-5429. doi: blood-2006-11-057208 [pii] 10.1182/blood-2006-11-057208
75. Kato M, Sanada M, Kato I et al (2009) Frequent inactivation of a20 in b-cell lymphomas. Nature 459(7247): 712-716. doi: nature07969 [pii] 10.1038/nature07969
76. Honma K, Tsuzuki S, Nakagawa M et al (2009) Tnfaip3/a20 functions as a novel tumor suppressor gene in several subtypes of non-hodgkin lymphomas. Blood 114(12): 2467-2475. doi: blood-2008-12-194852 [pii] 10.1182/blood-2008-12-194852
77. Navarro A, Bea S, Fernandez V et al (2009) Microrna expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas. Cancer Res 69(17): 7071-7078. doi: 0008-5472.CAN-09-1095 [pii] 10.1158/0008-5472.CAN-09-1095
78. Mao X, Young BD, Lu Y.J. (2007) The application of single nucleotide polymorphism microarrays in cancer research. Curr Genomics 8(4): 219-228
79. Gondek LP, Tiu R, O'keefe CL et al (2008) Chromosomal lesions and uniparental disomy detected by snp arrays in mds, mds/mpd, and mds-derived aml. Blood 111(3): 1534-1542. doi: blood-2007-05-092304 [pii] 10.1182/blood-2007-05- 092304
80. Beroukhim R, Lin M, Park Y et al (2006) Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide snp arrays. PLoS Comput Biol 2(5): e41. doi: 10.1371/journal.pcbi.0020041
81. Lo KC, Bailey D, Burkhardt T et al (2008) Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100 k snp mapping arrays and comparison with copy number abnormalities defined by bac array comparative genomic hybridization. Genes Chromosomes Cancer 47(3): 221-237. doi: 10.1002/gcc.20524
82. Fitzgibbon J, Smith LL, Raghavan M et al (2005) Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 65(20): 9152-9154. doi: 65/20/9152 [pii] 10.1158/0008-5472.CAN-05-2017
83. Stephens PJ, Mcbride DJ, Lin ML et al (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276): 1005-1010. doi: nature08645 [pii] 10.1038/nature08645
84. Stephens PJ, Greenman CD, Fu B et al (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144(1): 27-40. doi: S0092-8674(10)01377-2 [pii] 10.1016/j.cell.2010.11.055
85. Coquelle A, Pipiras E, Toledo F et al (1997) Expression of fragile sites triggers intrachromo-somal mammalian gene amplification and sets boundaries to early amplicons. Cell 89(2): 215-225. doi: S0092-8674(00)80201-9 [pii]
86. Fu K, Weisenburger DD, Greiner TC et al (2005) Cyclin d1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 106(13): 4315-4321. doi: 2005-04-1753 [pii] 10.1182/blood-2005-04-1753
87. Gesk S, Klapper W, Martin-Subero JI et al (2006) A chromosomal translocation in cyclin d1-negative/cyclin d2-positive mantle cell lymphoma fuses the ccnd2 gene to the igk locus. Blood 108(3): 1109-1110. doi: 108/3/1109 [pii] 10.1182/blood-2006-01-0015
88. Shiller SM, Zieske A, Holmes H 3rd et al (2011) Cd5-positive, cyclind1-negative mantle cell lymphoma with a translocation involving the ccnd2 gene and the igl locus. Cancer Genet 204(3): 162-164. doi: S0165-4608(10)00479-6 [pii] 10.1016/j.cancergencyto.2010.08.016
89. Herens C, Lambert F, Quintanilla-Martinez L et al (2008) Cyclin d1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin d2 overexpression. Blood 111(3): 1745-1746. doi: 111/3/1745 [pii] 10.1182/blood-2007-10-120824
90. Shaughnessy J Jr, Gabrea A., Qi Y et al (2001) Cyclin d3 at 6p21 is dysregulated by recurrent chromosomal translocations to immuno-globulin loci in multiple myeloma. Blood 98(1): 217-223
91. Sonoki T, Harder L, Horsman DE et al (2001) Cyclin d3 is a target gene of t(6;14) (p21.1;q32.3) of mature b-cell malignancies. Blood 98(9): 2837-2844
92. Wlodarska I, Dierickx D, Vanhentenrijk V et al (2008) Translocations targeting ccnd2, ccnd3, and mycn do occur in t(11;14)-negative mantle cell lymphomas. Blood 111(12): 5683-5690. doi: blood-2007-10-118794 [pii] 10.1182/blood-2007-10-118794
93. Mozos A, Royo C, Hartmann E et al (2009) Sox11 expression is highly specific for mantle cell lymphoma and identifies the cyclin d1-negative subtype. Haematologica 94(11): 1555-1562. doi: 94/11/1555 [pii] 10.3324/haematol.2009. 010264
94. Ek S, Dictor M, Jerkeman M et al (2008) Nuclear expression of the non b-cell lineage sox11 transcription factor identifies mantle cell lymphoma. Blood 111(2): 800-805. doi: blood-2007-06-093401 [pii] 10.1182/blood-2007-06-093401
95. Martin P, Chadburn A, Christos P et al (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27(8): 1209-1213. doi: JCO.2008.19.6121 [pii] 10.1200/JCO.2008.19.6121
96. Ondrejka SL, Lai R, Smith SD et al (2011) Indolent mantle cell leukemia: a clinicopatho-logical variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96(8): 1121-1127. doi: haematol.2010.036277 [pii] 10.3324/haematol.2010.036277
97. Eve HE, Furtado MV, Hamon MD et al (2009) Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 27(32): e189-e190. doi: JCO.2009.23.9731 [pii] 10.1200/JCO.2009.23.9731, author reply e191
98. Zhang Y, Xiong Y, Yarbrough W.G. (1998) Arf promotes mdm2 degradation and stabilizes p53: Arf-ink4a locus deletion impairs both the rb and p53 tumor suppression pathways. Cell 92(6): 725-734. doi: S0092-8674(00)81401-4 [pii]
99. Serrano M, Hannon GJ, Beach D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin d/cdk4. Nature 366(6456): 704-707. doi: 10.1038/366704a0
100. Jacobs JJ, Scheijen B, Voncken JW et al (1999) Bmi-1 collaborates with c-myc in tumorigenesis by inhibiting c-myc-induced apoptosis via ink4a/arf. Genes Dev 13(20): 2678-2690
101. Salaverria I, Espinet B, Carrio A et al (2008) Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes Cancer 47(12): 1086-1097. doi: 10.1002/gcc.20609
102. Tort F, Hernandez S, Bea S et al (2005) Checkpoint kinase 1 (chk1) protein and mrna expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19(1): 112-117. doi: 2403571 [pii] 10.1038/sj.leu.2403571
103. Tort F, Hernandez S, Bea S et al (2002) Chk2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-hodgkin lymphomas. Blood 100(13): 4602-4608. doi: 10.1182/blood-2002-04- 10782002-04-1078 [pii]
104. Hernandez L, Hernandez S, Bea S et al (1999) C-myc mrna expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia 13(12): 2087-2093
105. Chen RW, Bemis LT, Amato CM et al (2008) Truncation in ccnd1 mrna alters mir-16-1 regulation in mantle cell lymphoma. Blood 112(3): 822-829. doi: blood-2008-03-142182 [pii] 10.1182/blood-2008-03-142182
106. He L, Thomson JM, Hemann MT et al (2005) A microrna polycistron as a potential human oncogene. Nature 435(7043): 828-833. doi: nature03552 [pii] 10.1038/nature03552
107. Parry-Jones N., Matutes E, Morilla R et al (2007) Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may in fluence prognosis: a study of 60 cases by fish. Br J Haematol 137(2): 117-124. doi: BJH6526 [pii] 10.1111/j.1365-2141.2007.06526.x
108. Katzenberger T, Kienle D, Stilgenbauer S et al (2008) Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. Br J Haematol 142(4): 538-550. doi: BJH7199 [pii] 10.1111/j.1365-2141.2008.07199.x
109. Nagy B, Lundan T, Larramendy ML et al (2003) Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of myc is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120(3): 434-441. doi: 4121 [pii]
110. Schaffner C, Idler I, Stilgenbauer S et al (2000) Mantle cell lymphoma is characterized by inactivation of the atm gene. Proc Natl Acad Sci USA 97(6): 2773-2778. doi: 10.1073/pnas.050400997050400997 [pii]
111. Tabe Y, Sebasigari D, Jin L et al (2009) Mdm2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 15(3): 933-942. doi: 15/3/933 [pii] 10.1158/1078-0432.CCR-08- 0399
112. Marzec M, Kasprzycka M, Lai R et al (2006) Mantle cell lymphoma cells express predominantly cyclin d1a isoform and are highly sensitive to selective inhibition of cdk4 kinase activity. Blood 108(5): 1744-1750. doi: blood-2006-04-016634 [pii] 10.1182/blood-2006-04-016634
113. Kridel R, Meissner B, Rogic S et al (2012) Whole transcriptome sequencing reveals recurrent notch1 mutations in mantle cell lymphoma. Blood. doi: blood-2011-11-391474 [pii] 10.1182/blood-2011-11-391474